Trial Condition(s):

Atopic dermatitis

In-home use test of the new modified Diprobase formulation to assess the safety and tolerability in infants and children under physician’s control

Bayer Identifier:

19690

ClinicalTrials.gov Identifier:

NCT03441568

EudraCT Number:

2017-004334-29

Study Completed

Trial Purpose

To investigate the safety and tolerability of the modified Diprobase formulation over 14 days in infants and children with a history of Atopic Dermatitis (AD).

Inclusion Criteria
No Inclusion Criteria Available
Exclusion Criteria
No Exclusion Criteria Available

Trial Summary

Enrollment Goal
40
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Diprobase (BAY987534)
Accepts Healthy Volunteers
Yes

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

West Timperley Medical Centre

Altrincham, United Kingdom, WA14 5PF

Status
Completed
 

Trial Design